{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-006123","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2022-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.797870+00:00","generated_at":"2026-06-23T09:03:45.833012+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CEO J. Melville Engle to retire effective Oct 31, 2022; board initiates successor search","bullets":["CEO Engle announces retirement, stepping down as Chairman and board member effective October 31, 2022.","Transition & Separation Agreement provides $524,400 severance (1 yr base salary), $139K pro-rata bonus, and accelerated vesting of 300,000 RSUs.","Governance committee conducting CEO search; Engle will remain in role through October 31 for orderly transition.","CFO Bob Myers cited Engle's role in acquiring zPREDICTA and expanding oncology drug development offerings."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-006123","json":"https://secwatch.observer/filing/0001171843-22-006123.json","markdown":"https://secwatch.observer/filing/0001171843-22-006123.md","text":"https://secwatch.observer/filing/0001171843-22-006123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/0001171843-22-006123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/f8k_091622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:03:45.833012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dd3a95937","claim":"J. Melville Engle departed as Chief Executive Officer at Axe Compute Inc..","evidence_excerpt":"On September 15, 2022, J. Melville Engle announced that he will retire as the Chief Executive Officer of Predictive Oncology Inc. (the “Company”) and as Chairman and a member of the Company’s board of directors, effective October 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322006123/0001171843-22-006123-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}